Go Pro
→ Bezos… DOOMED (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
$1.22
+2.5%		$0.99
$0.74
▼
$1.74
$38.36M0.05149,039 shs146,206 shs
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
$4.14
$5.15
$0.72
▼
$20.32
$39.91M1.0565,254 shs41,394 shs
IN8bio, Inc. stock logo
INAB
IN8bio
$1.08
+0.9%		$1.13
$0.88
▼
$2.73
$10.65M0.339,847 shs20,305 shs
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
$6.44
+4.0%		$6.01
$8.50
▼
$23.00
$40.23MN/A37,647 shs16,335 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
0.00%-12.86%+8.93%+18.45%-24.22%
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
0.00%-2.13%-13.03%-43.67%+73.22%
IN8bio, Inc. stock logo
INAB
IN8bio
0.00%+0.93%-10.74%-24.48%-46.00%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
+3.96%+2.12%+0.55%-17.82%-50.84%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
$1.22
+2.5%		$0.99
$0.74
▼
$1.74
$38.36M0.05149,039 shs146,206 shs
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
$4.14
$5.15
$0.72
▼
$20.32
$39.91M1.0565,254 shs41,394 shs
IN8bio, Inc. stock logo
INAB
IN8bio
$1.08
+0.9%		$1.13
$0.88
▼
$2.73
$10.65M0.339,847 shs20,305 shs
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
$6.44
+4.0%		$6.01
$8.50
▼
$23.00
$40.23MN/A37,647 shs16,335 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
0.00%-12.86%+8.93%+18.45%-24.22%
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
0.00%-2.13%-13.03%-43.67%+73.22%
IN8bio, Inc. stock logo
INAB
IN8bio
0.00%+0.93%-10.74%-24.48%-46.00%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
+3.96%+2.12%+0.55%-17.82%-50.84%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
3.00
Buy$5.00309.84% Upside
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
2.67
Moderate Buy$5.0020.77% Upside
IN8bio, Inc. stock logo
INAB
IN8bio
2.00
Hold$4.00270.37% Upside
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest INAB, EDSA, ATNM, and IZTC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
IN8bio, Inc. stock logo
INAB
IN8bio
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/29/2026
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
Brookline Capital Markets logo
Brookline Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
6/24/2026
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
$35.09M1.09N/AN/A$1.31 per share0.93
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
N/AN/AN/AN/A$0.45 per shareN/A
IN8bio, Inc. stock logo
INAB
IN8bio
N/AN/AN/AN/A$2.82 per shareN/A
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
-$48.82M$0.36N/AN/AN/AN/A-100.85%-47.89%N/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
-$7.19M-$1.69N/AN/AN/AN/A-560.22%-105.74%N/A
IN8bio, Inc. stock logo
INAB
IN8bio
-$19.44M-$1.62N/AN/AN/AN/A-91.18%-76.93%11/5/2026 (Estimated)
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest INAB, EDSA, ATNM, and IZTC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q3 2026
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
-$0.4350-$0.60-$0.1650-$0.60N/AN/A
8/6/2026Q2 2026
IN8bio, Inc. stock logo
INAB
IN8bio
-$0.3437-$0.25+$0.0937-$0.25N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/AN/AN/AN/AN/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
N/AN/AN/AN/AN/A
IN8bio, Inc. stock logo
INAB
IN8bio
N/AN/AN/AN/AN/A
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/A
10.25
10.25
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
N/A
2.76
2.76
IN8bio, Inc. stock logo
INAB
IN8bio
N/A
8.21
8.21
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
27.50%
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
5.50%
IN8bio, Inc. stock logo
INAB
IN8bio
92.05%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/A

Insider Ownership

CompanyInsider Ownership
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
0.60%
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
24.40%
IN8bio, Inc. stock logo
INAB
IN8bio
14.50%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
2531.44 million29.32 millionOptionable
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
179.64 million7.29 millionNot Optionable
IN8bio, Inc. stock logo
INAB
IN8bio
189.86 million8.43 millionNot Optionable
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
296.25 millionN/AN/A

Recent News About These Companies

Invizyne Technologies (NASDAQ:IZTC) Trading Down 7.9% - Time to Sell?
September 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31014040
Institutional investors own a significant stake of 42% in Invizyne Technologies, Inc. (NASDAQ:IZTC)
February 13, 2025  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/institutional-investors-own-significant-stake-122811776.html
What’s in a Name: Out with Invizyne, In with eXoZymes
February 12, 2025  |  genengnews.comG
Invizyne Technologies rebrands as eXoZymes with new ticker EXOZ
February 11, 2025  |  msn.comhttps://www.msn.com/en-us/technology/tech-companies/invizyne-technologies-rebrands-as-exozymes-with-new-ticker-exoz/ar-AA1yLfmv
Invizyne announces corporate name change to eXoZymes
February 11, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/invizyne-announces-corporate-name-change-to-exozymes-1034336391
Why Invizyne Technologies, Inc.’s (IZTC) Stock Is Up 12.35%
February 4, 2025  |  aaii.comA
Why Invizyne Technologies, Inc.’s (IZTC) Stock Is Up 10.33%
January 30, 2025  |  aaii.comA
Invizyne technologies CEO Michael Heltzen buys $20,345 in stock
January 21, 2025  |  msn.comhttps://www.msn.com/en-us/technology/tech-companies/invizyne-technologies-ceo-michael-heltzen-buys-20-345-in-stock/ar-AA1xAdEg
Invizyne Technologies Inc trading resumes
January 1, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/invizyne-technologies-inc-trading-resumes-1034183742
Invizyne Technologies Inc trading halted, volatility trading pause
January 1, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/invizyne-technologies-inc-trading-halted-volatility-trading-pause-1034183743
Michael Heltzen Buys 1,984 Shares of Invizyne Technologies Inc. (NASDAQ:IZTC) Stock
November 20, 2024  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-iztc-insider-buying-and-selling-2024-11-20/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
NVIDIA logo over a computer chip, server racks, and an upward-trending green stock price chart.
NVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout Is
By Thomas Hughes | August 27, 2026
Data center hallway with rows of server racks and cables, plus a monitoring room with computer screens in the background.
AI Token Costs Are Changing the Hardware vs. Software Debate
By Jeffrey Neal Johnson | September 6, 2026
Illustration of a computer chip on a circuit board with an upward green stock chart line in a server room.
Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
By Thomas Hughes | August 31, 2026
Shoppers browse folded and hanging clothing in a retail apparel store with shelves and racks displayed.
3 Retail Stocks to Watch After a Big Consumer Earnings Week
By Dan Schmidt | August 29, 2026
Illustration of ascending coin and cash stacks with an upward arrow line graph symbolizing financial growth.
From High Dividend Growth to High Yield, These 3 Stocks Just Boosted Dividend Payouts
By Leo Miller | September 2, 2026
Actinium Pharmaceuticals stock logo

Actinium Pharmaceuticals NYSE:ATNM

$1.22 +0.03 (+2.52%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$1.23 +0.01 (+0.82%)
As of 09/18/2026 06:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Edesa Biotech stock logo

Edesa Biotech NASDAQ:EDSA

$4.14 0.00 (0.00%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$4.10 -0.04 (-1.09%)
As of 09/18/2026 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

IN8bio stock logo

IN8bio NASDAQ:INAB

$1.08 +0.01 (+0.93%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$1.07 -0.01 (-0.93%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation. The Company is also developing INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed Glioblastoma (GBM). The preclinical pipeline includes a novel γδ T cell engager platform, INB-600, which activates and expands γδ T cells in vivo for deep target cell depletion and is being developed for oncology and autoimmune indications.

Invizyne Technologies stock logo

Invizyne Technologies NASDAQ:IZTC

$6.44 +0.25 (+3.96%)
As of 09/18/2026

Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas